Notice to Eligible Shareholders
Released
Released
Announcement PDF
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
13 April 2023
Dear Shareholder
NOTICE TO ELIGIBLE SHAREHOLDERS
On 3 April 2023, Avecho Biotechnology Limited (ACN 056 482 403) (ASX:AVE) (Avecho or Company)
announced that it is undertaking a non-renounceable entitlement offer of 1 new fully paid ordinary share (New
Share) for every 1 existing share held by Eligible Shareholders on the Record Date, at an issue price of $0.006
per New Share to raise up to approximately $11 million (before costs) (Entitlement Offer). Participants in the
Entitlement Offer will also be issued 3 free attaching options exercisable at $0.012 each and expiring 3 years
from the date of issue (New Options) for every 2 New Shares subscribed under the Entitlement Offer.
Eligible Shareholders who have taken up their full Entitlement may also apply (in excess of their Entitlement)
for New Shares and New Options not subscribed for by other Eligible Shareholders at the same issue price as
under the Entitlement Offer. Refer to the Prospectus for details regarding the allocation policy for the Additional
Share Facility.
The Entitlement Offer is being conducted under a prospectus (Prospectus) pursuant to section 713 of the
Corporations Act 2001 (Cth) (Corporations Act). Capitalised terms used, but not defined, in this letter have
the meaning ascribed to them in the Prospectus.
Eligibility criteria
Eligible Shareholders include persons who:
•
are registered as a holder of fully paid ordinary shares in Avecho as at 7:00 pm (AEST) on Thursday, 6
April 2023 (Record Date);
•
have a registered address in Australia or New Zealand as noted on the Company’s share register, or are
a Shareholder that the Company has otherwise determined is eligible to participate in the Entitlement
Offer;
•
are not in the United States and are not a person (including nominees or custodians) acting for the account
or benefit of a person in the United States (to the extent such person holds existing shares for the account
or benefit of such person in the United States); and
•
are eligible under all applicable securities laws to receive an offer under the Entitlement Offer,
(Eligible Shareholder).
The Company has determined, pursuant to section 9A(3) of the Corporations Act and Listing Rule 7.7.1(a) of
the ASX Listing Rules, that it would be unreasonable to make offers to shareholders in countries outside of
Australia or New Zealand in connection with the Entitlement Offer. This is due to the legal and regulatory
requirements in countries outside of Australia or New Zealand and the potential costs to the Company of
complying with these requirements, compared with the relatively small number of shareholders in those
countries, the relatively small number of existing shares they hold and the relatively low value of New Shares
to which those shareholders would otherwise be entitled to subscribe for.
Page 1 of 3
Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403
Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168
avecho.com.au
Prospectus
This letter is not an offer document but is a notice of some key terms and conditions of the Entitlement Offer.
Full details of the Entitlement Offer are set out in the Prospectus, which has today been despatched to Eligible
Shareholders. If you have opted to receive communications by post, a copy of the Prospectus, Investor
Presentation and a personalised Entitlement and Acceptance Form (which contains details of your
Entitlements under the Entitlement Offer) will be mailed to your address on the Company’s shares register. If
you have opted to receive communications electronically, you will receive an email containing a link to access
an electronic copy of the Prospectus and your personalised Entitlement and Acceptance Form.
Eligible Shareholders can also access a copy of the Prospectus, Investor Presentation, and personalised
Entitlement and Acceptance Form at the following link: www.computersharecas.com.au/aveoffer.
The Company has also launched an online Investor Hub where Shareholders can engage directly with
management and access additional information. You can access the Hub at:
https://ave.freshamplify.com/welcome.
Actions which may be taken by Eligible Shareholders
If you are an Eligible Shareholder, you may take any one of the following actions:
•
•
•
•
take up all of your Entitlement;
take-up all of your Entitlement and apply for additional New Shares under the Additional Share Facility;
take up part of your Entitlement and allow the balance to lapse; or
do nothing, in which case your entitlement will lapse and you will receive no value for those lapsed
Entitlements.
Your entitlements under the Entitlement Offer may have value and it is important you determine whether to
take up (in whole or in part) or do nothing in respect of your entitlement. There are a number of matters that
you should consider in relation to taking up your entitlement. You should ensure that you understand the tax
consequences of any action that you take, and you should consider seeking advice from your professional
adviser.
The Entitlement Offer is non-renounceable and therefore the entitlements that you would have been entitled
to, or the underlying shares that you may have subscribed for, will not be offered for sale and no amount will
be payable to you. This is not an offer of New Shares to you, nor an invitation for you to apply for New Shares
or New Options.
Taking up an entitlement
If you wish to take up all, or part of, your entitlements under the Entitlement Offer, please pay your application
monies by following the instructions set out on the personalised Entitlement and Acceptance Form. Application
Monies must be received before 5:00pm (AEST) on Wednesday, 3 May 2023. Nominees must not take up
Entitlements under the Entitlement Offer on behalf of, or send any documents related to the Entitlement Offer
to, any person in the United States.
Further information
For further information regarding the Entitlement Offer, please contact the offer information line on 1300 850
505 (within Australia) or +61 3 9415 5000 (outside Australia) between 8.30am to 5.00pm (AEST) Monday to
Friday during the offer period. Alternatively, contact your stockbroker, solicitor, accountant or other
professional adviser.
On behalf of the Board, I thank you for your ongoing support of the Company.
Yours sincerely,
Dr Gregory Collier
Chairman
Page 2 of 3
3462-3123-9714, v. 5
Important information
This letter is issued by Avecho. This letter is not a prospectus or offering document under Australian law or under any other
law. It is for information purposes only and does not constitute an offer, invitation or recommendation to subscribe for,
retain or purchase any entitlements or securities in Avecho in any jurisdiction. This letter does not constitute financial
product advice and does not and will not form any part of any contract for the acquisition of entitlements or Avecho
securities.
This letter may not be released or distributed in the United States. This letter does not constitute an offer to sell, or the
solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of, any person in the
United States. No action has been or will be taken to register, qualify or otherwise permit a public offering of the New
Shares or New Options in any jurisdiction. In particular, the New Shares and New Options have not been, and will not be,
registered under the United States Securities Act of 1933 (U.S. Securities Act) or the securities laws of any state or other
jurisdiction of the United States. Accordingly, the entitlements, the New Shares and New Options may not be issued to,
purchased or traded by, or taken up or exercised by, any person in the United States or any person acting for the account
or benefit of a person in the United States except pursuant to an exemption from, or in a transaction not subject to, the
registration requirements of the U.S. Securities Act and applicable United States state securities laws. The entitlements,
New Shares and New Options to be offered in the Entitlement Offer will only be offered outside the United States in
"offshore transactions" (as defined in Rule 902(h) of the Securities Act) in reliance on Regulation S under the U.S.
Securities Act.
Page 3 of 3
3462-3123-9714, v. 5
Share your feedback
Discover